Eli Lilly & Co. vs. Pacira BioSciences, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | PCRX | |
|---|---|---|
| Market Cap | $1.09 trillion | $944.73 million |
| Revenue (TTM) | — | $746.16 million |
| Net Income (TTM) | — | $14.64 million |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | PCRX | |
|---|---|---|
| P/E Ratio | — | 65.71 |
| Price / Book | — | 1.41 |
| Price / Sales | — | 1.27 |
LLY and PCRX split the valuation factors evenly.
Profitability
| LLY | PCRX | |
|---|---|---|
| Net Margin | — | 1.96% |
| Return on Equity | — | 2.18% |
LLY and PCRX split the profitability factors evenly.
Risk & Sentiment
| LLY | PCRX | |
|---|---|---|
| Short Interest | 1.29% | 9.32% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, PCRX overview, PCRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.